Highlights Enzychem Lifesciences Corporation

Equities

A183490

KR7183490002

End-of-day quote Korea S.E. Other stock markets 23:00:00 04/07/2024 BST			5-day change	1st Jan Change
1,874 ^KRW	+2.07%		-4.73%	+3.08%

04-05	Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares.	CI
04-05	Enzychem Lifesciences Corporation authorizes a Buyback Plan.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares.	04-05	CI
Enzychem Lifesciences Corporation authorizes a Buyback Plan.	04-04	CI
Enzychem Lifesciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Enzychem Lifesciences Announces Completion of Clinical Study Report for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis	09/03/22	CI
Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences	02/02/22	CI
Hanmi Pharma to Manufacture COVID-19 Vaccine Developed by India's Zydus Cadila	12/01/22	MT
Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries with Enzychem Lifesciences	04/01/22	CI
Enzychem Lifesciences Corporation to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea	26/11/21	CI
Enzychem Lifesciences Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis	08/11/21	CI
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis	20/10/21	CI
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of Ec-18 in Chemoradiation-Induced Oral Mucositis	13/09/21	CI
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program	20/04/21	CI
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis	06/04/21	CI
Enzychem Lifesciences Corporation announced that it expects to receive KRW 50 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Kiwoom Securities Co., Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm, and other investors	03/11/20	CI
Enzychem Lifesciences Corp. Announces U.S. Food and Drug Administration Acceptance of Phase 2 Study of EC-18	13/08/20	CI
Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome due to COVID-19 Pneumonia	13/07/20	CI
Enzychem Lifesciences Initiates Phase 2 Study for EC-18 in Preventing Acute Respiratory Distress Syndrome due to Novel Coronavirus Pneumonia	14/05/20	CI
Enzychem Lifesciences Announces Plans to Advance Clinical Trial in South Korea for EC-18 as a Potential Therapeutic for Covid-19 Infection	17/03/20	CI
Enzychem Lifesciences Corporation Enters into Collaborative Agreement with the Armed Forces Radiobiology Research Institute	06/12/19	CI
Enzychem Lifesciences Corporation Presents EC-18 NASH Development Update At the Liver Meeting 2019	21/11/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Enzychem Lifesciences Corporation

Equities

A183490

KR7183490002

Highlights

Filters